# Diabetic Lancing Device Market

> Diabetic Lancing Device Market Research Report By type (push button safety lancets, pressure activated safety lancets, side button safety lancets), by gauge (17/18g, 21g, 23g, 25g, 28g,& 30g), by penetration depth, by end-user-forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.43%
- **2024:** $ 1.6 Billion
- **2025:** $ 1.7 Billion
- **2035:** $ 3.17 Billion
- **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Bayer AG (DE), Terumo Corporation (JP), Medtronic(US), Johnson & Johnson (US), Nipro Corporation (JP), Sanofi (FR), Becton Dickinson and Company (US)

**Report ID:** MRFR/MED/4060-HCR · **Pages:** 90 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/diabetic-lancing-device-market-5507

---

## Market Summary

## **Diabetic Lancing Device Market Overview**

Diabetic Lancing Device Market Size was valued at USD 1.5 Billion in 2023. The Global Diabetic Lancing Device industry is projected to grow from USD 1.6 Billion in 2024 to USD 2.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.80% during the forecast period (2024 - 2032). Diabetes is a global epidemic affecting an estimated 382 million people worldwide. The WHO projects that diabetes will be the 7th leading cause of death by 2030. An estimated 4 million people die annually from the complications associated with diabetes.

Therefore, if the current trend associated with the prevalence of diabetes continues over the coming years, the number of diabetic patients across the globe would be tremendous after a decade. Increasing prevalence of diabetes will result in the rising demand for devices and products to monitor and control diabetes, eventually leading to increased consumption of lancets. Thus, the demand for lancets is expected to be enormous in the coming future.

Lancets are one of the widely used alternative device to obtain the blood samples. These devices are receiving global recognition and acceptance due to its several convenient characteristics which gives them an edge over the traditional methods for vein puncture. Some of the important features of the safety lancets are painless vein puncture, easy handling, and safety while using. The major applications of the lancets are HIV screening test, capillary blood micro sampling and cholesterol test, blood group test, coagulation tests, haemoglobin, allergy tests, and many other blood based tests.

According to the International Diabetes Federation (IDF), approximately 29.2 million people in the US are estimated suffer from diabetes in 2015. Japan had approximately 7.2 million. in 2015.

Rising prevalence of diabetic population, increasing awareness for [blood glucose monitoring](https://www.marketresearchfuture.com/reports/diabetic-lancing-device-market-5507) device and increased awareness of safety measures in order to avoid the infectious diseases are some of the significant factors of the increased awareness and use of lancets. However, the price erosion is a major issue that is negatively impacting the diabetes management devices. Moreover, significant changes in reimbursement policies in the US for blood glucose monitors, particularly the ongoing impact to the private insurance sector are some of the factors restraining the growth of diabetic lancing device market.

## **Diabetic Lancing Device Market Segmentation**

The global diabetic lancing devices market is segmented on the basis of type, gauge, penetration depth, and end user.

On the basis of type, the diabetic lancing device market for diabetic lancing devices it is segmented into safety lancets and standard lancets. The safety lancets are further categorized into push-button safety lancets, pressure activated safety lancets, and side button safety lancets. The pen needles is further categorized into standard pen needles and safety pen needles.

On the basis of gauge, the diabetic lancing device market for diabetic lancing devices it is segmented into 17/18g, 21g, 23g, 25g, 28g, 30g, and others.

On the basis of penetration depth, the diabetic lancing devices market is segmented into 0.8 mm to 1.0 mm, 1.1 mm to 1.5 mm, 1.6 mm to 2.0 mm, 2.1 mm to 2.5 mm, 2.5 mm to 3.0 mm, and others.

On the basis of the end users, it is segmented into hospitals & clinics, diagnostic centers & medical institutions, home care & home diagnostics, research & academic laboratories, and others.

## **Diabetic Lancing Device Market Regional Analysis**

The global diabetic lancing device market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

Europe is projected to hold the largest share of the global diabetic lancing device market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. According to the International Diabetes Federation (IDF), in 2015 approximately 59.8 million people had diabetes in Europe. HTL Strefa and Sarstedt are two European companies which have marked their presence on the global level as a major manufacturer of lancets and safety lancets in the world.

The Americas holds a key share in diabetic lancing device market. Moreover, North America dominated the overall market in terms of revenue in 2016. In the U.S., ongoing uncertainty as to the future of the Affordable Care Act and the Trump Administration’s repeal and replace initiative may further impact the market.

Asia Pacific is estimated to be the fastest region to grow at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. A large number of lancet manufacturers are from developing Asian countries such as China, India, Japan and Republic of Korea mainly because of the low labour cost and low R&D cost. China being one of the highly populated and technologically advanced developing countries, has a major number of lancets manufacturers.

Some of the renowned Chinese Safety Lancet manufacturers are Guangzhou Improve Medical Instruments Co, Huang and KDL China.

The Middle East & Africa diabetic lancing device market is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of diabetic lancing devices.

## **Diabetic Lancing Device Market Key Players**

- B. Braun Melsungen AG
- Terumo Corporation
- Becton Dickinson
- Sanofi
- F. Hoffmann-La Roche AG
- Bayer AG, Novo Nordisk A S
- Eli Lilly and Company
- Owen Mumford Ltd
- Medtronic
- Ypsomed Holding AG
- Sarstedt AG & Co
- Greiner Bio One
- Abbott Laboratories
- HTL-STREFA S.A, Improve Medical
- UltiMed, Inc.
- [Allison Medical](https://www.allisonmedical.com/), Inc.
- Artsana S.p.a.
- VOGT MEDICAL
- Perrigo Diabetes Care
- MedExel Co. Ltd
- ARKRAY Inc.
- Simple Diagnostics
- Stat Medical
- Terumo
- Trividia Health

## Market Drivers

### Rising Prevalence of Diabetes

The increasing incidence of diabetes worldwide is a primary driver for the Diabetic Lancing Device Market. According to recent statistics, the number of individuals diagnosed with diabetes has surged, with estimates suggesting that over 500 million people are currently living with the condition. This growing patient population necessitates effective blood glucose monitoring solutions, thereby propelling demand for lancing devices. As diabetes management becomes more critical, healthcare providers and patients alike are seeking reliable and user-friendly lancing devices. This trend indicates a robust market potential, as manufacturers strive to innovate and enhance their product offerings to meet the needs of a diverse patient demographic.

### Increased Awareness and Education

Growing awareness regarding diabetes management and the importance of regular blood glucose monitoring is significantly influencing the Diabetic Lancing Device Market. Educational initiatives by healthcare organizations and advocacy groups are empowering patients with knowledge about diabetes care. This heightened awareness is likely to lead to increased adoption of lancing devices, as patients recognize the necessity of monitoring their blood sugar levels. Furthermore, market data indicates that regions with robust educational programs exhibit higher usage rates of lancing devices, suggesting a correlation between awareness and market growth. As education continues to expand, the demand for effective lancing solutions is expected to rise.

### Shift Towards Home Healthcare Solutions

The trend towards home healthcare is reshaping the Diabetic Lancing Device Market. Patients increasingly prefer managing their diabetes at home, driven by the convenience and comfort it offers. This shift has led to a surge in demand for user-friendly lancing devices that can be easily utilized in a home setting. Market data reveals that the home healthcare segment is experiencing rapid growth, with more patients opting for self-monitoring solutions. Manufacturers are responding to this trend by developing lancing devices that are not only efficient but also designed for ease of use. This evolution in patient care is likely to sustain market growth in the coming years.

### Technological Innovations in Lancing Devices

Technological advancements play a pivotal role in shaping the Diabetic Lancing Device Market. Innovations such as smart lancing devices equipped with Bluetooth connectivity and mobile applications are gaining traction. These devices not only facilitate easier blood sampling but also enable users to track their glucose levels in real-time. The integration of advanced features is likely to enhance user experience and adherence to diabetes management protocols. Market data suggests that the demand for such technologically advanced devices is on the rise, as patients increasingly prefer solutions that offer convenience and improved functionality. This trend is expected to drive growth in the market as manufacturers invest in research and development.

### Regulatory Support and Reimbursement Policies

Supportive regulatory frameworks and favorable reimbursement policies are crucial drivers for the Diabetic Lancing Device Market. Governments and health authorities are increasingly recognizing the importance of diabetes management, leading to the establishment of policies that facilitate access to necessary medical devices. Enhanced reimbursement options for lancing devices are encouraging patients to utilize these essential tools for blood glucose monitoring. Market data indicates that regions with robust reimbursement frameworks witness higher adoption rates of lancing devices, suggesting that financial support plays a significant role in market dynamics. As regulatory environments continue to evolve, the market is likely to benefit from increased accessibility and affordability.

## Future Outlook

The Diabetic Lancing Device Market is projected to grow at a 6.43% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and rising demand for user-friendly devices.

**New opportunities:**

- Development of smart lancing devices with integrated data analytics capabilities.
- Expansion into emerging markets with tailored pricing strategies.
- Partnerships with telehealth platforms for remote monitoring solutions.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Type: Safety Lancets (Largest) vs. Standard Lancets (Fastest-Growing)

In the Diabetic Lancing Device Market, Safety Lancets hold a significant portion of the market share, primarily due to their user-friendly design and emphasis on patient safety. These devices are favored by consumers for their reduced risk of needle-stick injuries and ease of use, which enhances compliance among diabetic patients. Conversely, Standard Lancets, while not as dominant, are witnessing a rapid increase in adoption, particularly among budget-conscious users who prioritise cost-effectiveness over safety features. This shift suggests a dynamic landscape where patient preferences are evolving, impacting overall market shares.

Safety Lancets: Dominant vs. Standard Lancets: Emerging

Safety Lancets, characterized by their automatic retractable needles and designed to minimize pain and risk, occupy a predominant position in the Diabetic Lancing Device Market. They cater to a safety-conscious demographic, particularly among those who self-manage their diabetes at home. In contrast, Standard Lancets are emerging as a popular option due to their lower cost, appealing to users who are more price-sensitive. While less safe, they offer adequate functionality for routine blood sampling. The competition between these two types reflects a balancing act between safety and affordability in diabetes care, with each segment appealing to different market needs and patient preferences.

### By Gauge: 21g (Largest) vs. 28g (Fastest-Growing)

In the Diabetic Lancing Device Market, the gauge segment showcases diverse options, with the 21g gauge dominating market share due to its balance of comfort and effectiveness. The 28g gauge, while smaller, is seeing rapid adoption among consumers who prioritize reduced pain during lancing, driving a notable increase in its market presence. As patients seek ease of use and have a low tolerance for discomfort, the demand for these varying gauge sizes highlights the need for manufacturers to cater to diverse preferences. Growth trends within the gauge segment are primarily influenced by the increasing awareness of diabetes management and technological advancements in lancing devices. The 28g is becoming the go-to choice for those looking for pain-free alternatives, showcasing a perfect blend of innovation and user-centric design. Moreover, with the rise in diabetes cases globally, manufacturers are compelled to innovate, fostering competition that accelerates product development and enhancement across multiple gauge sizes.

21g (Dominant) vs. 28g (Emerging)

The 21g gauge in the diabetic lancing device market retains its position as the dominant choice due to its efficacy in blood sample collection, providing reliability without excessive pain. Users have found it to be an optimal choice, balancing comfort and sample adequacy, making it particularly favored among both new and experienced diabetes patients. On the other hand, the 28g gauge is emerging rapidly, thanks to advancements in technology that enhance the user experience by minimizing pain during blood sampling. Its thinner needle attracts a growing demographic preferring less invasive options, thus expanding the segment's reach. As healthcare professionals increasingly recommend this gauge for its patient-friendly attributes, the 28g gauge is poised for substantial growth within the sector, marking a significant shift in consumer preferences.

### By Penetration Depth: 1.1 mm to 1.5 mm (Largest) vs. 0.8 mm to 1.0 mm (Fastest-Growing)

The diabetic lancing device market shows a distinct segmentation based on penetration depth, with '1.1 mm to 1.5 mm' emerging as the leading segment in terms of market share. This segment benefits from its widespread acceptance due to optimal balance between comfort and effectiveness for users managing diabetes. Additionally, '0.8 mm to 1.0 mm' is rapidly gaining traction for its less invasive approach, appealing particularly to those who prioritize pain reduction in their daily glucose monitoring routines. As awareness increases, these segments will likely capture more attention in the healthcare landscape. Growth trends indicate a shift towards finer needles, driving the '0.8 mm to 1.0 mm' segment as the fastest-growing option. Consumers increasingly seek solutions that provide less painful sampling experiences. Research into enhanced device technology also fuels this growth, offering better user experiences with safe, effective lancing options. Market players are focusing on innovation and education, pushing for broader acceptance of these finer penetration depths, which also align with the growing demand for patient-centric diabetic care tools.

1.1 mm to 1.5 mm (Dominant) vs. 0.8 mm to 1.0 mm (Emerging)

The '1.1 mm to 1.5 mm' penetration depth segment is regarded as dominant within the diabetic lancing device market, recognized for its ability to provide reliable blood samples without excessive discomfort. Healthcare providers often recommend this range due to its efficacy in various skin types while reducing the risk of complications such as bruising. On the other hand, the '0.8 mm to 1.0 mm' segment represents an emerging trend, driven by the growing consumer demand for less painful lancing devices. This segment is particularly appealing to children and adults who fear needle pain, increasing its adoption. Both segments illustrate the evolving landscape of diabetic care, focusing on comfort, convenience, and effective monitoring systems.

### By End User: Home Care & Home Diagnostics (Largest) vs. Hospitals & Clinics (Fastest-Growing)

In the Diabetic Lancing Device Market, the end user segment is diverse, with significant shares distributed across various categories. Home Care & Home Diagnostics holds the largest market share, driven by the increasing prevalence of diabetes and the demand for convenient self-monitoring solutions. Hospitals & Clinics are also a considerable segment, providing professional care but with a growing trend towards at-home management of diabetes. Diagnostic Centers & Medical Institutions and Research & Academic Laboratories serve specialized roles, while others form a smaller proportion of the market.

Home Care & Home Diagnostics (Dominant) vs. Hospitals & Clinics (Emerging)

Home Care & Home Diagnostics is currently the dominant segment in the Diabetic Lancing Device Market, as patients increasingly prefer the convenience of managing their diabetes at home. This segment benefits from the rise of [telehealth](https://www.marketresearchfuture.com/reports/veterinary-telehealth-market-42407) and remote monitoring solutions, allowing easier access to healthcare resources. On the other hand, Hospitals & Clinics are viewed as an emerging segment focusing on the integration of advanced lancing devices that offer improved accuracy and ergonomics. While they traditionally played a supportive role in diabetes management, advancements in technology and increasing awareness about diabetes management in clinical settings are contributing to their rapid growth.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for diabetic lancing devices, accounting for approximately 45% of the global market share. The region's growth is driven by increasing diabetes prevalence, technological advancements, and supportive healthcare policies. Regulatory bodies like the FDA have streamlined approval processes for innovative devices, further boosting market growth. The rising demand for home healthcare solutions is also a significant factor contributing to this trend.

The United States leads the North American market, followed by Canada. Key players such as Abbott Laboratories, Medtronic, and Johnson & Johnson dominate the competitive landscape, offering a range of advanced lancing devices. The presence of established healthcare infrastructure and high consumer awareness about diabetes management further enhances market opportunities. The competitive rivalry is intense, with companies continuously innovating to meet consumer needs.

### Europe : Emerging Regulatory Frameworks

Europe is the second-largest market for diabetic lancing devices, holding around 30% of the global market share. The region's growth is fueled by rising diabetes cases, an aging population, and increasing healthcare expenditure. Regulatory frameworks, such as the EU Medical Device Regulation, are evolving to ensure safety and efficacy, which is expected to enhance consumer trust and drive market growth. The demand for user-friendly and efficient devices is also on the rise, contributing to market expansion.

Germany, France, and the UK are the leading countries in this market, with Germany being the largest. Major players like Roche Diagnostics and Bayer AG are well-established, focusing on innovation and quality. The competitive landscape is characterized by a mix of multinational corporations and local manufacturers, all striving to capture market share through advanced product offerings and strategic partnerships. The emphasis on preventive healthcare is also shaping the market dynamics.

### Asia-Pacific : Rapidly Growing Market

Asia-Pacific is witnessing rapid growth in the diabetic lancing device market, accounting for approximately 20% of the global share. The region's growth is driven by increasing diabetes prevalence, urbanization, and rising disposable incomes. Governments are implementing initiatives to improve healthcare access, which is expected to further boost demand for diabetic care products. The growing awareness of diabetes management among the population is also a significant factor contributing to market growth.

China and India are the leading countries in this region, with significant market potential due to their large populations. Key players like Terumo Corporation and Nipro Corporation are expanding their presence to cater to the growing demand. The competitive landscape is becoming increasingly dynamic, with both local and international companies vying for market share. Innovations in product design and functionality are key strategies employed by companies to differentiate themselves in this competitive market.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually emerging in the diabetic lancing device market, holding about 5% of the global market share. The growth is primarily driven by increasing diabetes prevalence, urbanization, and improving healthcare infrastructure. Governments are focusing on enhancing healthcare access and awareness, which is expected to drive demand for diabetic care products. The region's diverse population presents unique challenges and opportunities for market players.

Countries like South Africa and the UAE are leading the market, with increasing investments in healthcare technology. The competitive landscape is characterized by a mix of local and international players, with companies like Sanofi and Becton Dickinson expanding their operations. The focus on preventive healthcare and patient education is shaping market dynamics, creating opportunities for innovative product offerings and partnerships.

## Competitive Benchmarking

The Diabetic Lancing Device Market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of diabetes and the growing demand for effective blood glucose monitoring solutions. Key players such as Roche Diagnostics (CH), Abbott Laboratories (US), and Becton Dickinson and Company (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Roche Diagnostics (CH) focuses on innovation, particularly in developing advanced lancing devices that minimize pain and improve user experience. Meanwhile, Abbott Laboratories (US) emphasizes digital transformation, integrating smart technology into their devices to provide real-time data analytics for users. Becton Dickinson and Company (US) is pursuing regional expansion, particularly in emerging markets, to capitalize on the rising demand for diabetes management solutions.

The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing. The collective influence of these major players shapes the market dynamics, as they continuously innovate and adapt to changing consumer needs, thereby fostering a competitive environment that encourages advancements in product offerings.

In August 2025, Abbott Laboratories (US) announced the launch of a new lancing device that incorporates Bluetooth technology, allowing users to sync their blood glucose readings with mobile applications. This strategic move not only enhances user convenience but also aligns with the growing trend of digital health solutions, positioning Abbott as a leader in integrating technology with diabetes management. The introduction of this device is likely to attract tech-savvy consumers who prioritize connectivity and data tracking in their health management routines.

In September 2025, Roche Diagnostics (CH) unveiled a partnership with a leading telehealth provider to offer remote monitoring solutions alongside their lancing devices. This collaboration aims to provide comprehensive diabetes care by enabling healthcare professionals to monitor patients' glucose levels remotely. Such strategic alliances are indicative of a broader trend towards integrated healthcare solutions, which may enhance patient outcomes and foster loyalty among users.

In October 2025, Becton Dickinson and Company (US) revealed plans to invest in sustainable manufacturing practices for their lancing devices, aiming to reduce their carbon footprint significantly. This initiative reflects a growing emphasis on sustainability within the healthcare sector, as consumers increasingly favor environmentally responsible products. By prioritizing sustainability, Becton Dickinson not only addresses consumer concerns but also positions itself favorably in a market that is progressively leaning towards eco-friendly practices.

As of October 2025, the competitive trends in the Diabetic Lancing Device Market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing product offerings and expanding market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the sophisticated demands of consumers in an increasingly complex market.

## Report Scope

| MARKET SIZE 2024 | 1.596(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.699(USD Billion) |
| MARKET SIZE 2035 | 3.169(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.43% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Bayer AG (DE), Terumo Corporation (JP), Medtronic (US), Johnson & Johnson (US), Nipro Corporation (JP), Sanofi (FR), Becton Dickinson and Company (US) |
| Segments Covered | type, gauge, penetration depth, by end-user-forecast till 2035 |
| Key Market Opportunities | Integration of smart technology in Diabetic Lancing Devices enhances user experience and data management. |
| Key Market Dynamics | Technological advancements and regulatory changes are reshaping the competitive landscape of the diabetic lancing device market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current market valuation of the Diabetic Lancing Device Market?**
A: As of 2024, the market valuation was 1.596 USD Billion.

**Q: What is the projected market size for the Diabetic Lancing Device Market by 2035?**
A: The market is projected to reach 3.169 USD Billion by 2035.

**Q: What is the expected CAGR for the Diabetic Lancing Device Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 6.43%.

**Q: Which companies are considered key players in the Diabetic Lancing Device Market?**
A: Key players include Roche Diagnostics, Abbott Laboratories, Bayer AG, and Medtronic, among others.

**Q: What are the two main types of lancing devices in the market?**
A: The two main types are Safety Lancets and Standard Lancets, with valuations of 1.598 USD Billion and 1.571 USD Billion, respectively.

**Q: How does the gauge of lancing devices impact market segmentation?**
A: The gauge segment includes various sizes, with 21g and 30g gauges valued at 0.6 USD Billion and 0.4 USD Billion, respectively.

**Q: What is the significance of penetration depth in the Diabetic Lancing Device Market?**
A: Penetration depth ranges from 0.8 mm to 3.0 mm, with the 1.1 mm to 1.5 mm segment valued at 0.9576 USD Billion.

**Q: Which end-user segments are driving the Diabetic Lancing Device Market?**
A: End-user segments include Hospitals & Clinics and Home Care, each valued at 0.956 USD Billion.

**Q: What trends are influencing the growth of the Diabetic Lancing Device Market?**
A: Trends include increasing demand for home diagnostics and advancements in lancing technology.

**Q: How do the market valuations of different segments compare?**
A: For instance, the Safety Lancets segment is valued higher than Standard Lancets, indicating a potential shift in consumer preference.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/diabetic-lancing-device-market-5507*